Update and new trends in antiemetic therapy: The continuing need for novel therapies

Annals of Oncology

Volumn 22, Issue 1, 2011, Pages 30-38

  Feyer, P ^a   Jordan, K ^b  

^a Nuclear Medicine   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Aprepitant; Breakthrough; Casopitant; CINV; Palonosetron

Indexed keywords

ANTIEMETIC AGENT; APREPITANT; BENZAMIDE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BUTYROPHENONE DERIVATIVE; CANNABINOID DERIVATIVE; CASOPITANT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOLASETRON MESILATE; DOPAMINE RECEPTOR BLOCKING AGENT; DRONABINOL; FOSAPREPITANT; GRANISETRON; ITRACONAZOLE; METOCLOPRAMIDE; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; ORAL CONTRACEPTIVE AGENT; PALONOSETRON; PHENOTHIAZINE DERIVATIVE; PHENYTOIN; PLACEBO; SEROTONIN 3 ANTAGONIST; TERFENADINE; TROPISETRON; UNINDEXED DRUG; WARFARIN;

ACNE; AGITATION; ANEMIA; ANOREXIA; ANTIEMETIC ACTIVITY; APPETITE; AREA POSTREMA; AREA UNDER THE CURVE; ASTHENIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL TRIAL; CONSTIPATION; CYTOTOXICITY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; DRUG TOLERABILITY; DYSPHORIA; ENZYME INHIBITION; EPIGASTRIC DISCOMFORT; EUPHORIA; FATIGUE; HALLUCINATION; HICCUP; HUMAN; INDIGESTION; INSOMNIA; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SEDATION; SENSORY NERVE; SIDE EFFECT; SINGLE DRUG DOSE; WEIGHT GAIN;

EID: 78650375895     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq600     Document Type: Review

References (66)

1. Lohr L. Chemotherapy-induced nausea and vomiting. Cancer J 2008; 14: 85-93.
2. Jordan K, Schmoll HJ, Aapro MS. Comparative activity of antiemetic drugs. Crit Rev Oncol Hematol 2007; 61: 162-175.
3. NCCN. National Comprehensive Cancer Network: Antiemesis, Clinical Practice Guidelines in Oncology-v.1. 2010. www.nccn.org (4 October 2010, date last accessed).
4. Hesketh PJ, Van Belle S, Aapro M et al. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 2003; 39: 1074-1080.
5. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008; 358: 2482-2494.
6. Roila F, Hesketh PJ, Herrstedt J. Prevention of chemotherapy- and radiotherapyinduced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006; 17: 20-28.
7. Kris MG, Hesketh PJ, Somerfield MR et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006; 24: 2932-2947.
8. Kris MG, Radford JE, Pizzo BA et al. Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin. J Natl Cancer Inst 1997; 89: 817-818.
9. Darmani NA, Ray AP. Evidence for a re-evaluation of the neurochemical and anatomical bases of chemotherapy-induced vomiting. Chem Rev 2009; 109: 3158-3199.
10. Carpenter DO, Briggs DB, Strominger N. Responses of neurons of canine area postrema to neurotransmitters and peptides. Cell Mol Neurobiol 1983; 3: 113-126.
11. Geling O, Eichler H. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 2005; 23: 1289-1294.
12. Gralla R, Osoba D, Kris M et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 1999; 17: 2971-2994.
13. Kris MG, Hesketh PJ, Herrstedt J et al. Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 2005; 13: 85-96.
14. Herrstedt J, Koeller JM, Roila F et al. Acute emesis: moderately emetogenic chemotherapy. Support Care Cancer 2005; 13: 97-103.
15. Roila F, Herrstedt J, Aapro M et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010; 21 (Suppl 5): v232-v243.
16. Reddy GK, Gralla RJ, Hesketh PJ. Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis. Support Cancer Ther 2006; 3: 140-142.
17. www.clinicaltrials.gov/ct2/results?term=rolapitant (4 October 2010, date last accessed).
18. Hesketh P, Grunberg S, Gralla R et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003; 21: 4112-4119.
19. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003; 97: 3090-3098.
20. Schmoll HJ, Aapro MS, Poli-Bigelli S et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 2006; 17: 1000-1006.
21. Warr D, Grunberg SM, Gralla RJ et al. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer 2005; 41: 1278-1285.
22. Van Belle S, Lichinitser MR, Navari RM et al. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer 2002; 94: 3032-3041.
23. Depre M, Van Hecken A, Oeyen M et al. Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur J Clin Pharmacol 2005; 61: 341-346.
24. Shadle CR, Lee Y, Majumdar AK et al. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol 2004; 44: 215-223.
25. Massaro AM, Lenz KL. Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting. Ann Pharmacother 2005; 39: 77-85.
26. McCrea JB, Majumdar AK, Goldberg MR et al. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 2003; 74: 17-24.
27. Dando TM, Perry CM. Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 2004; 64: 777-794.
28. Nygren P, Hande K, Petty KJ et al. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Cancer Chemother Pharmacol 2005; 55: 609-616.
29. de Jonge M, Huitema A, Holtkamp M et al. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. Cancer Chemother Pharmacol 2005; 56: 370-378.
30. Grunberg SM. Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. Ann Oncol 2007; 18: 233-240.
31. Vardy J, Chiew KS, Galica J et al. Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 2006; 94: 1011-1015.
32. Aapro M, Fabi A, Nole F et al. Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 2010; 21: 1083-1088.
33. Grunberg SM, Dugan M, Muss H et al. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Cancer 2009; 17: 589-594.
34. Kris MG, Gralla RJ, Tyson LB et al. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 1989; 7: 108-114.
35. Moreno I, Rosell R, Abad A et al. Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients. Eur J Cancer 1992; 28A: 1344-1347.
36. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research. J Clin Oncol 1997; 15: 124-130.
37. Aapro MS, Thuerlimann B, Sessa C et al. A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis. Ann Oncol 2003; 14: 291-297.
38. Tramer MR, Carroll D, Campbell FA et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001; 323: 16-21.
39. Osoba D, Zee B, Warr D et al. Quality of life studies in chemotherapy-induced emesis. Oncology 1996; 53 (Suppl 1): 92-95.
40. Ritter HJ, Gralla R, Hall S et al. Efficacy of intravenous granisetron to control nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. Cancer Invest 1998; 16: 87-93.
41. Rojas C, Thomas AG, Alt J et al. Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol 2010; 626: 193-199.
42. Aapro MS, Grunberg SM, Manikhas GM et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006; 17: 1441-1449.
43. Gralla R, Lichinitser M, Van Der Vegt S et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003; 14: 1570-1577.
44. Eisenberg P, Figueroa-Vadillo J, Zamora R et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003; 98: 2473-2482.
45. Saito M, Aogi K, Sekine I et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 2009; 10: 115-124.
46. Sekine I, Saito M, Aogi K et al. Palonosetron (PALO) versus granisetron (GRAN), both combined with dexamethasone (DEX) in preventing chemotherapy-induced nausea and vomiting (CINV) associated with cisplatin- or anthracycline plus cyclophosphamide-based regimens: results of a phase III trial in Japanese patients. J Clin Oncol 2008; 26: (Abstr 20749).
47. Einhorn LH, Brames MJ, Dreicer R et al. Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 2007; 15: 1293-1300.
48. Rapoport BL, Jordan K, Boice JA et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, doubleblind study. Support Care Cancer 2010; 18: 423-431.
49. Jordan K, Kinitz I, Voigt W et al. Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy. Eur J Cancer 2009; 45: 1184-1187.
50. Bubalo J, Seelig F, Karbowicz S, Maziarz RT. Randomized open-label trial of dolasetron for the control of nausea and vomiting associated with high-dose chemotherapy with hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001; 7: 439-445.
51. Junagadhwalla M, Chilton J, Gentile T et al. Prolonged administration of aprepitant does not increase toxicity in patients undergoing high dose chemotherapy and autologous stem cell transplant. Blood 2005; 106.
52. Barnet C, Oholendt M, Popat U et al. Evaluation of aprepitant for treatment of acute and delayed chemotherapy-induced nausea and vomiting in patients undergoing autologous stem cell transplantation. Blood 2004; 104.
53. Szer JGA, Roberts AW et al. Aprepitant in the prevention of acute and delayed nausea and vomiting following haematopoietic stem cell transplantation: a pilot study. Bone Marrow Trans 2006; 37: 112.
54. Stiff P, Fox-Geimann MP, Kiley K et al. A prospective, randomized phase III trial of oral ondansetron and dexamethasone alone vs. oral ondansetron, dexamethasone and the NK-1 inhibitor, aprepitant (Emend) for the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation. Blood 2009; 114: (Abstr 2267).
55. Paul B, Trovato JA, Thompson J et al. Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support. J Oncol Pharm Pract 2010; 1: 45-51.
56. Grunberg S, Chua DT, Roila F, Herrstedt J. Phase III randomized double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting (CINV). J Clin Oncol 2010; 28: (Abstr 9021).
57. King AG. Complete rescue from established emesis by the NK-1 receptor antagonist, casopitant mesylate, in cisplatin-induced delayed emesis in the ferret. J Clin Oncol 2006; 24: (Abstr 18601).
58. Grunberg SM, Rolski J, Strausz J et al. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebocontrolled trial. Lancet Oncol 2009; 6: 549-558.
59. Herrstedt J, Apornwirat W, Shaharyar A et al. Casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting: phase III trial results in patients receiving moderately emetogenic chemotherapy. J Clin Oncol 2009; 27: 5363-5369.
60. Navari RM. Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and anti-nausea activities. Curr Opin Investig Drugs 2008; 9: 774-785.
61. Blum R, Adams LM, Johnson BM et al. Effect of casopitant, a novel neurokinin-1 (NK-1) receptor antagonist for prevention of chemotherapy induced nausea and vomiting (CINV), on the pharmacokinetics (PK) and pharmacodynamics (PD) of steady-state warfarin. J Clin Oncol 2008; 26: (Abstr 20587).
62. Bymaster FP, Nelson DL, DeLapp NW et al. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res 1999; 37: 107-122.
63. Zhang W, Bymaster FP. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors. Psychopharmacology (Berl) 1999; 141: 267-278.
64. Navari RM, Einhorn LH, Loehrer PJ Sr et al. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer 2007; 15: 1285-1291.
65. Passik SD, Navari RM, Jung SH et al. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. Cancer Invest 2004; 22: 383-388.
66. Navari R, Gray SE, Carr AC. Olanzapine versus Aprepitant for the prevention of chemotherapy induced nausea and vomiting (CINV): a randomized phase III trial. J Clin Oncol 2010; 28: # 9020.